REDMILE — 2023 Investments

2 investments dated 2023 · listed companies and verified rows first · show all

Morphimmunemorphimmune.comJun 2023

HealthtechWest Lafayette, US

Philip Low, Ph.D.(Director)Sunil Singhal, M.D.(Director)Isaac Barchas(Director)Clay B. Siegall, Ph.D.(Executive Officer, Director)Ronald Martell(Director)inFranklyn Prendergast, M.D., Ph.D.(Director)

Co-investorsEcoR1 Capital Arsenal Bridge Venture Janus Henderson Investors

Orbital Therapeuticsorbitaltx.com in 𝕏Apr 2023 · $270MAcquired

A pharmaceutical company developing therapeutics across oncology, hematology, neuroscience, immunology, and cardiovascular disease with a pipeline of 50 compounds targeting 40+ disease areas.

BiotechHealthtechMedical Devices

Co-investorsAndreessen Horowitz ARCH Venture Partners iGlobe Partners Agent Capital Newpath Partners

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.